Rosina Samadani

Member Since 2021

Rosina Samadani

CEO

Oculogica

New York City Area

Healthcare technology aficionado with 24 years of experience. Currently CEO of Oculogica, a medical device company founded by a neurosurgeon and dedicated to developing breakthrough technology to fundamentally transform the diagnosis of concussions and Traumatic Brain Injuries with its non-invasive, fast, patent-protected and peer-reviewed technology - Raised $11M+ from accredited investors, angel groups and venture capital - Conducted multiple FDA interactions for disruptive, breakthrough diagnostics via the de novo and 510(k) pathways - Led the procurement of $500K+ funding via NIH and FDA grants - Established successful relationships with major research centers and the Department of Defense - Implemented QA systems - Authored multiple patents - Winner of the 2018 Angel Capital Association Luis Villalobos Award for Innovative Startup - Winner of the 2019 NIMBLE Health Vanguard Award for entrepreneurship in healthcare - 2020 Fast Company Most Creative People in Business Previously, Founder and President of Truth On Call, earth's fastest verified healthcare practitioner input. Launched January 2010. Previously, Founder and President of Capella Advisors, a strategic consulting firm to the healthcare industry providing support of data and digital strategy, product commercialization, portfolio strategy, market entry, and business development. Founded 2004. With McKinsey and Company for 7 years serving in the healthcare practice on efforts ranging from clinical development to product marketing. PhD in Biomedical Engineering from Northwestern University and BS and MS in Mechanical Engineering from MIT.

SKILLS

  • Strategy
  • Business Development
  • Product Marketing

COMPANY INFO

Oculogica

The EyeBOX is as powerful as it is easy to use. In under 4 minutes, Oculogica’s proprietary technology collects and analyzes over 100,000 data points across 67-domains of eye movement to generate an objective assessment of concussion that is unique to each patient. Detailed, real-time information on TBI and concussion facilitates rapid and precise diagnosis and improved patient outcomes. The EyeBOX requires no baseline data nor individual calibration, and therefore results cannot be influenced by patient will. Baseline-free Proprietary EyeBOX technology generates quick and accurate analysis without the need for pre-incident patient data. Objective 67-point analysis enables greater diagnostic precision and improved patient outcomes. Unlike current standards of care, the EyeBOX goes beyond symptoms to measure brain function. Easy to Use Simple, calibration-free testing requires no literacy, language fluency or the ability to follow special directions. Accurate evaluation can be achieved in pre-verbal and verbally impaired patients.

AREA OF FOCUS

  • Neuro-Diagnostics
  • Brain Injury
  • Concussion

INDUSTRY

Health

© 2023 Newsweek Forum, LLC. All rights reserved. | Terms and Conditions and Privacy Policy | Newsweek® and the other denoted terms and the related trade dress are a non-exclusive list of the trademarks of Newsweek, LLC. in the U.S. and/or other countries. Newsweek, LLC trademarks and trade dress may not be used in connection with any product or service that is not Newsweek, LLC, in any manner that is likely to cause confusion among customers, or any manner that disparages Newsweek, LLC. This site contains the trademarks, service marks, and logos of third parties and such trademarks and service marks are the property of their respective owners and not owned by Newsweek, LLC. Such third party trademark owners may or may not be affiliated with, connected to, or sponsored by Newsweek, LLC. These third party marks include but are not limited to Newsweek®, which is a registered trademark of and the property of Newsweek, LLC.